Industry News
Biosignal woos potential customers in oil, gas
Sydney-based Biosignal (ASX:BOS) has piqued the interest of some major international oil and gas companies. [ + ]
Aussie biotech getting better at global partnering: report
The Australian biotechnology industry is showing new signs of maturity, evidenced by a substantial increase in international alliance activity, according to a new analysis by industry consultant Innovation Dynamics. [ + ]
GBC leads way in export success
GBC Scientific has recently completed a major shipment of atomic absorption spectrometers to India. The single order was for 58 instruments and a large volume of accessories and consumable items. GBC is an Australian manufacturer, with these instruments (and others) designed, developed and manufactured at the company's international head office in Dandenong, Victoria.
[ + ]Vaxine awarded $2.5m bioterrorism grant
Privately-held vaccine developer Vaxine and Flinders University have been awarded a grant of US$2.5 million over three years by the US National Institutes of Health (NIH) to develop vaccines that protect against bioterrorist attacks. [ + ]
Biota aims to raise $10m
Melbourne-based Biota Holdings (ASX:BTA) is aiming to raise more than AUD$10 million in a non-renounceable share offer to existing shareholders. [ + ]
Mesoblast to start commercial stem cell production
Melbourne-based Mesoblast (ASX:MSB) has signed a process development and manufacturing agreement with US life sciences company Cambrex Corporation (NYSE:CMB) for the large scale production of Mesoblast's adult stem cells. [ + ]
Local pharma firms to distribute Funhaler
Perth-based biomedical devices developer Visiomed Group (ASX:VSG) has successfully competed negotiations with three pharmaceutical wholesale distributors in Australia for the distribution of its Funhaler incentive asthma spacer into Australian pharmacies. [ + ]
Phosphagenics claims promising insulin results
Melbourne's Phosphagenics (ASX:POH) has successfully delivered insulin through the skin of animals using its patented transdermal drug delivery system TPM-01. [ + ]
Ventracor chalks up first revenues
Ventracor (ASX:VCR) has received its first revenues, in the form of a cheque from the University of Maryland Medical Centre as payment for a VentrAssist left ventricular assist device (LVAD) recently implanted in a patient as part of its US clinical trial. [ + ]
Psiron puts back cancer trial results
Sydney oncology therapy developer Psiron (ASX:PSX) has announced a delay in reporting the results of its first phase I clinical trial of its cancer-slaying CVA 21 viral therapy in melanoma patients because of delays in access to supplies of the virus. [ + ]
Premier subsidiary to go ahead with lung device
Premier Bionics (ASX:PBI) subsidiary Pulmosonix will continue with the development of its PulmoScreen device which measures lung damage following the successful completion of a proof-of-concept trial. [ + ]
Amrad to change its name
Melbourne's Amrad Corporation (ASX:AML) will be seeking approval from shareholders to change its name. [ + ]
Medical Therapies narrows focus, issues new prospectus
Unable to secure sufficient funds with its first attempt at an IPO, Sydney-based Medical Therapies has issued a replacement prospectus which CEO Llewellyn Casbolt believes has "uncluttered and demystified the company and its technologies". [ + ]
Eqitx, Mimotopes sign partnering deal
Eqitx (ASX:EQX) and PharmAust (ASX:PAA) subsidiary Mimotopes have signed a partnership deal to jointly develop new targets for therapeutic or diagnostic approaches. [ + ]
Cryptome to chase opps in vascular field
Melbourne biopharma Cryptome Pharmaceuticals (ASX:CRP) has signed a collaboration agreement with the University of Virginia for the further discovery of compounds to treat 'vascular leak' -- a major component of inflammatory disorders and tissue damage associated with stroke, heart attacks and MS. [ + ]
